CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company, has launched the fifth annual Patient Advocacy Leadership (PAL) Awards program for non-profit organizations that serve the lysosomal storage disorder (LSD) patient community. The PAL Awards program seeks to spark innovative collaborations in disease awareness programs and patient support initiatives around the world. Genzyme’s Patient Advocacy Leadership Awards (PAL Awards) program is open to non-profit organizations that serve the lysosomal storage disorder (LSD) patient community and designed to support disease awareness programs and patient support initiatives around the world.
Through this competitive program, funds are granted to nonprofit, charitable patient organizations that seek funding for new initiatives that support the LSD community. In its fifth year, the program is evolving in 2015 to focus more on initiatives that involve two or more organizations collaborating together to support their broader LSD community, including regional and country collaborations and across various disease communities. The goal is to highlight and support programs that enable knowledge and best practice sharing, and work to unite the broader LSD community. For the first time this year, translation services will be provided to patient organizations seeking to apply in languages other than English. Submissions will be accepted now through September 30, 2015, when an External Review Committee will evaluate and select recipients. A total of $50,000 will be awarded through this year’s program.
“Patient organizations play a vital role in facilitating access to care and provide support for patients and their families around the world, and therefore supporting their work is critical to optimizing patient care and increasing disease awareness,” said Genzyme’s Head of Global Rare Diseases, Richard Peters, MD, Ph.D. “From travelling photo exhibits and video projects, to digital technology applications and mentoring programs, previous grant recipients have demonstrated their creativity, intensity and passion to improve the lives of patients living with LSDs through their submissions. We look forward to supporting more of these great efforts.”
Since 2011, more than $400,000 has been awarded to 37 patient organizations around the world to support disease awareness, community mobilization, non-profit development and good governance activities. For more information on the Genzyme PAL Awards program, or to apply for a grant, please visit www.genzymeadvocacyawards.com.
About Lysosomal Storage Disorders
Lysosomal storage disorders (LSDs) are a group of more than 40 diseases. Each is caused by a genetic problem that results in the deficiency or malfunction of particular enzymes needed to remove waste material from cells. These waste molecules then accumulate, or are stored, in cell lysosomes (smaller compartments within the cells), disrupting cell function and causing a variety of symptoms. All LSDs are progressive, meaning that without treatment, they worsen over time. Each LSD is caused by a different genetic problem and enzyme deficiency. Because these disorders are extremely rare – even the most common, Gaucher disease, only affects an estimated 10,000 people worldwide – it can be difficult to find information about them.
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at www.genzyme.com.
Genzyme® is a registered trademark of Genzyme Corporation. All rights reserved.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.